A New Marker for Early Diagnosis of Pneumoperitoneum-Related Acute Kidney Injury: Insulin-Like Growth Factor-1 (IGF-1)

What Was Tested

In this not phased trial, researchers set out to test IGF-1 LR3.

In their study, to show the effect of pneumoperitoneum on acute kidney injury in patients scheduled for laparoscopic surgery, NGAL and IGF-1 values will be measured before, after and 24 hours after pneumoperitoneum, and these values will be compared.

In their study, the researchers aimed to investigate the effect of pneumoperitoneum applied on acute kidney injury in patients who underwent laparoscopic surgery.

Creatinine and NGAL have been used successfully in the follow-up of acute kidney injury.

It had 1 arm (groups): IGF (other).

Creatinine and NGAL have been used successfully in the follow-up of acute kidney injury. In their study, in order to show the effect of pneumoperitoneum on acute kidney injury in patients scheduled for laparoscopic surgery, NGAL and IGF-1 values will be measured before, after and 24 hours after pneumoperitoneum, and these values will be compared.

The registry classes the interventions as diagnostic test.

Who Took Part

Enrollment: 25 actual participants took part.

It was open to people of any sex aged from 18 years up to 70 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Patients aged 18-70 years of both sexes. ASA I-III Patients.

The full record lists 2 inclusion and 18 exclusion criteria; among the exclusions: chronic kidney disease,; chronic renal failure,; acute renal failure,.

How the Study Was Run

It was run as a single-group and open-label study.

Nothing was hidden in this open-label IGF-1 LR3 study: the participants and staff both knew the treatment.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2023-02-08 with completion listed for 2023-03-30.

It ran at 1 site in Turkey (Türkiye).

Its stated primary purpose is diagnostic.

What Was Measured

The main thing measured (primary outcome): Diagnosis of acute kidney injury in the early postoperative period with IGF-1 (insulin like growth factor-1) (time frame: before pneumoperitoneum, after pneumoperitoneum, and at the postoperative 24th hour).

What This Means in Plain Language

Put simply, this is a not phased trial of IGF-1 LR3 in 25 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the IGF-1 LR3 compound page, all human trials.